Murphy Capital Management Inc. Sells 650 Shares of Becton Dickinson and Co (NYSE:BDX)

Murphy Capital Management Inc. decreased its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 8.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 7,374 shares of the medical instruments supplier’s stock after selling 650 shares during the period. Murphy Capital Management Inc.’s holdings in Becton Dickinson and were worth $1,841,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the stock. Oregon Public Employees Retirement Fund increased its position in Becton Dickinson and by 22,485.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 6,545,502 shares during the period. Norges Bank acquired a new position in Becton Dickinson and in the 4th quarter valued at approximately $515,703,000. Morgan Stanley increased its position in Becton Dickinson and by 133.0% in the 3rd quarter. Morgan Stanley now owns 2,771,269 shares of the medical instruments supplier’s stock valued at $723,303,000 after acquiring an additional 1,581,829 shares during the period. Mackenzie Financial Corp increased its position in Becton Dickinson and by 27.7% in the 4th quarter. Mackenzie Financial Corp now owns 1,943,752 shares of the medical instruments supplier’s stock valued at $437,966,000 after acquiring an additional 421,825 shares during the period. Finally, BlackRock Inc. increased its position in Becton Dickinson and by 1.9% in the 4th quarter. BlackRock Inc. now owns 19,384,283 shares of the medical instruments supplier’s stock valued at $4,367,665,000 after acquiring an additional 355,223 shares during the period. 84.89% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have issued reports on the stock. Barclays upped their price target on shares of Becton Dickinson and from $260.00 to $266.00 and gave the company an “equal weight” rating in a research report on Monday, April 15th. Zacks Investment Research cut shares of Becton Dickinson and from a “hold” rating to a “sell” rating in a research report on Monday, April 22nd. TheStreet upgraded shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research report on Tuesday, February 5th. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Finally, Piper Jaffray Companies increased their price objective on shares of Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 5th. Six equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $256.25.

Shares of NYSE BDX opened at $237.89 on Friday. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The firm has a market cap of $63.86 billion, a P/E ratio of 21.61, a P/E/G ratio of 1.70 and a beta of 1.16. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.97.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.58 by $0.12. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The firm had revenue of $4.16 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period last year, the firm earned $2.48 earnings per share. The business’s quarterly revenue was up 35.1% compared to the same quarter last year. Equities research analysts predict that Becton Dickinson and Co will post 12.07 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Friday, June 7th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.29%. The ex-dividend date is Thursday, June 6th. Becton Dickinson and’s dividend payout ratio (DPR) is 27.97%.

In other news, CEO Vincent A. Forlenza sold 11,340 shares of the stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $250.40, for a total value of $2,839,536.00. Following the completion of the sale, the chief executive officer now owns 227,250 shares in the company, valued at $56,903,400. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Ribo Alberto Mas sold 4,808 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $255.03, for a total transaction of $1,226,184.24. Following the completion of the sale, the executive vice president now owns 22,476 shares of the company’s stock, valued at approximately $5,732,054.28. The disclosure for this sale can be found here. Insiders sold 29,684 shares of company stock worth $7,518,574 over the last ninety days. Insiders own 0.12% of the company’s stock.

WARNING: “Murphy Capital Management Inc. Sells 650 Shares of Becton Dickinson and Co (NYSE:BDX)” was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/05/04/becton-dickinson-and-co-bdx-holdings-cut-by-murphy-capital-management-inc.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Why are percentage decliners important?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.